Rep. Kevin Hern (R-OK) Sells Boston Scientific (BSX) Stock
Oklahoma Congressman Kevin Hern sold his shares in Boston Scientific, continuing a trend of recent stock sales.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Kevin Hern (R-OK) sold between $1,001 and $15,000 of Boston Scientific Corporation ($BSX) stock on September 3, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed September 25, 2026.
Since the trade, $BSX is down 8.2% after 1 week, down 9.7% after 1 month and down 5.5% to date (from the $46.95 close on Sep 3, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Kevin Hern (R-OK)
- Status:
- Member — House
- State/District:
- OK-1
- Party:
- Republican
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Sep 25, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Boston Scientific Corporation ($BSX) | Sell | Sep 3, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
BSX
Boston Scientific Corporation
Key Points
- Congressman Kevin Hern sold shares of Boston Scientific Corporation valued between $1,001 and $15,000 on September 3, 2026.
- Boston Scientific's stock closed at $44.12 on the day of the sale, which is below its 52-week high of $105.65.
- Analysts generally recommend the stock as a 'buy,' with a mean price target of $59.24.
Get $BSX trade alerts by text
We text you when insiders, Congress or big funds trade $BSX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
Oklahoma Congressman Kevin Hern sold shares of Boston Scientific Corporation (NYSE: BSX) valued between $1,001 and $15,000 on September 3, 2026. This transaction falls in line with Hern's recent pattern of selling shares in various companies, including his previous sales of shares in PTC Inc. and UnitedHealth Group earlier in September.
Kevin Hern vs. the S&P 500
Hypothetical returns from Kevin Hern's disclosed trades, not real profit or advice. How we model this.
Inside Kevin Hern's Trade
Hern's sale was reported on September 25, 2026. The amount sold was between $1,001 and $15,000, reflecting a continued strategy of liquidating some of his stock holdings. The transaction occurred when Boston Scientific shares were priced at $44.12, which has been fluctuating within a 52-week range of $41.39 to $105.65.
Other Institutional Activity in Boston Scientific
Several notable institutional investors have adjusted their stakes in Boston Scientific recently. Blackrock Inc. trimmed its holdings by 2,135,425 shares, resulting in a total of 129,680,916 shares worth about $5.72 billion. Vanguard Capital Management LLC increased its stake by 674,889 shares, bringing its total to 97,087,553 shares valued at approximately $4.28 billion. State Street Corporation added 2,121,285 shares, ending with 70,111,196 shares worth around $3.09 billion.
Boston Scientific Corporation Stock Up 2.6%
As of the article's publication, Boston Scientific shares are trading at $44.12, close to the 50-day moving average of $46.18. The stock is currently well below its 52-week high of $105.65, suggesting a considerable decline from its peak.
Recent Earnings
Boston Scientific reported revenue of approximately $20.99 billion for the last fiscal year, growing by 7.5% compared to the previous year. The company's earnings per share (EPS) stood at $2.47, with a net margin of about 17.5%. The next earnings report is scheduled for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
Insider activity at Boston Scientific has been notable recently. On August 25, 2026, Director Susan E. Morano purchased 2,040 shares at an average price of $49.22, totaling about $100,408. Director David C. Habiger also bought shares on August 5, acquiring 2,100 shares at $47.59, worth approximately $99,937. Additionally, CEO Michael F. Mahoney purchased 186,240 shares at $48.33, totaling around $9 million.
Analysts Set New Price Targets
On October 14, 2026, Truist Securities maintained a 'Buy' rating on Boston Scientific with a revised price target of $51.00, down from $57.00. Barclays initiated coverage with an 'Equal-Weight' rating and a target of $48.00 on October 7, 2026. Citigroup and Wells Fargo also maintained their ratings with targets of $48.00, reflecting a cautious outlook on the stock's performance.
About Boston Scientific
Boston Scientific Corporation develops and sells medical devices tailored for various medical specialties, such as cardiology and surgical disciplines. The company operates in two primary segments: MedSurg and Cardiovascular. The recent insider trades and the ongoing stock sales by Congressman Hern indicate changing dynamics among the company's stakeholders and market conditions.
Bottom Line
Investors will be watching Boston Scientific closely, especially with the upcoming earnings report on October 28, 2026. Hern's recent stock sales could signal a strategic shift, and the 13F filings provide a snapshot of current institutional holdings, which may change in the future.
Related Filing Alerts
Source: Kevin Hern's STOCK Act disclosure on $BSX (Sep 3, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts